InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Howell Kelli Mari, Vice-Président Exécutif, Stratégies Cliniques. Officer active across 1 company, notably Alphatec Holdings, Inc.. Cumulatively, 6 filings have been recorded. History available since 29 April 2021. The latest transaction was filed on 5 August 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Howell Kelli Mari
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
6,050 shares@ US$8.034.9% of flowCommon StockSEC:0001415889-22-008433:0
2,940 shares@ US$10.940.0025% mcap3.1% of flowCommon StockSEC:0001179110-22-002366:0
25,000 shares0Common StockSEC:0001179110-22-001694:0
6,050 shares@ US$15.2314.9% of flowCommon StockSEC:0001179110-21-008020:0
17,525 shares@ US$14.8140.9% of flowCommon StockSEC:0001179110-21-005569:0
11,474 shares@ US$16.3329.6% of flowCommon StockSEC:0001179110-21-004763:0
6 of 6 declarations
About Howell Kelli Mari
Kelli Mari Howell is Executive Vice President, Clinical Strategies at Alphatec Holdings, Inc. She is responsible for leading clinical initiatives and product development strategy. Her expertise in healthcare and clinical operations management is essential to support the company's growth.
